Scheetz MH - Search Results

1

Use of therapeutic drug monitoring to characterize cefepime-related neurotoxicity.

Venugopalan V, Casaus D, Kainz L, Slaton CN, Hurst N, Bruzzone M, Hu C, Sword G, Cherabuddi K, Iovine N, Liu J, Scheetz MH, Rhodes N, Maranchick N, Peloquin CA, Klinker K, Alshaer MH. Venugopalan V, et al. Among authors: scheetz mh. Pharmacotherapy. 2023 Jan;43(1):6-14. doi: 10.1002/phar.2744. Epub 2022 Dec 2. Pharmacotherapy. 2023. PMID: 36401796

2

Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual.

Newman D, Scheetz MH, Adeyemi OA, Montevecchi M, Nicolau DP, Noskin GA, Postelnick MJ. Newman D, et al. Among authors: scheetz mh. Ann Pharmacother. 2007 Oct;41(10):1734-9. doi: 10.1345/aph.1K256. Epub 2007 Aug 28. Ann Pharmacother. 2007. PMID: 17726066

3

Posaconazole: an oral triazole with an extended spectrum of activity.

Rachwalski EJ, Wieczorkiewicz JT, Scheetz MH. Rachwalski EJ, et al. Among authors: scheetz mh. Ann Pharmacother. 2008 Oct;42(10):1429-38. doi: 10.1345/aph.1L005. Epub 2008 Aug 19. Ann Pharmacother. 2008. PMID: 18713852 Review.

4

Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and bla OXA gene status.

Esterly JS, Qi C, Malczynski M, Scheetz MH. Esterly JS, et al. Among authors: scheetz mh. Pharmacotherapy. 2010 Apr;30(4):354-60. doi: 10.1592/phco.30.4.354. Pharmacotherapy. 2010. PMID: 20334455

5

Differences in clinical outcomes in patients with vancomycin-resistant enterococci according to linezolid susceptibility.

Scheetz MH, Knechtel SA, Postelnick MJ, Malczynski M, Qi C. Scheetz MH, et al. Pharmacotherapy. 2010 Dec;30(12):1221-8. doi: 10.1592/phco.30.12.1221. Pharmacotherapy. 2010. PMID: 21114389

6

Life-years gained with meropenem over ciprofloxacin in penicillin-allergic patients with gram-negative bacilli sepsis: results of a probabilistic model.

Scheetz MH, Bolon MK, Esterly JS, Reddy P, Postelnick M, Lee TA. Scheetz MH, et al. Pharmacotherapy. 2011 May;31(5):469-79. doi: 10.1592/phco.31.5.469. Pharmacotherapy. 2011. PMID: 21923428 Review.

7

Impact of vancomycin treatment duration and dose on kidney injury.

Bosch K, McLaughlin MM, Esterly JS, Rhodes NJ, Postelnick MJ, Scheetz MH. Bosch K, et al. Among authors: scheetz mh. Int J Antimicrob Agents. 2014 Mar;43(3):297-8. doi: 10.1016/j.ijantimicag.2013.11.004. Epub 2013 Dec 7. Int J Antimicrob Agents. 2014. PMID: 24388114 No abstract available.

8

Unacceptably high error rates in Vitek 2 testing of cefepime susceptibility in extended-spectrum-β-lactamase-producing Escherichia coli.

Rhodes NJ, Richardson CL, Heraty R, Liu J, Malczynski M, Qi C, Scheetz MH. Rhodes NJ, et al. Among authors: scheetz mh. Antimicrob Agents Chemother. 2014 Jul;58(7):3757-61. doi: 10.1128/AAC.00041-14. Epub 2014 Apr 21. Antimicrob Agents Chemother. 2014. PMID: 24752253 Free PMC article.

9

Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemes.

Rhodes NJ, MacVane SH, Kuti JL, Scheetz MH. Rhodes NJ, et al. Among authors: scheetz mh. Clin Infect Dis. 2014 Sep 15;59(6):905-7. doi: 10.1093/cid/ciu402. Epub 2014 May 27. Clin Infect Dis. 2014. PMID: 24867788 No abstract available.

10

Evaluation of clinical outcomes in patients with Gram-negative bloodstream infections according to cefepime MIC.

Rhodes NJ, Liu J, McLaughlin MM, Qi C, Scheetz MH. Rhodes NJ, et al. Among authors: scheetz mh. Diagn Microbiol Infect Dis. 2015 Jun;82(2):165-71. doi: 10.1016/j.diagmicrobio.2015.03.005. Epub 2015 Mar 10. Diagn Microbiol Infect Dis. 2015. PMID: 25801780

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

215 results

Search Page